
1. mediterr j hematol infect dis. 2009 dec 22;1(3):e2009025. doi:
10.4084/mjhid.2009.025.

management hbv infection immunosuppressive treatment.

marzano a(1).

author information: 
(1)division gastroenterology hepatology, san giovanni battista hospital,
turin, italy.

the literature hepatitis b virus (hbv) immunocompromised patients is
heterogeneous refers mainly pre-antivirals era. currently, rational 
approach problem hepatitis b patients provides for: a) the
evaluation hbv markers liver condition subjects starting
immunosuppressive therapies (baseline), b) treatment antivirals
(therapy) active carriers, c) pre-emptive use antivirals (prophylaxis) 
in inactive carriers, especially undergoing immunosuppressive
therapies judged high risk, d) biochemical hbsag monitoring (or 
universal prophylaxis case high risk immunosuppression, in
onco-haematologic patients bone marrow transplantation) subjects with
markers previous contact hbv (hbsag-negative antihbc-positive), in
order prevent reverse seroconversion. moreover solid organ transplants it
is suggested strict adherence criteria allocation based the
virological characteristics recipients donors universal
prophylaxis therapy nucleos(t)ides analogs.

doi: 10.4084/mjhid.2009.025 
pmcid: pmc3033125
pmid: 21415959 

